CN117794544A - 实体瘤治疗用医药组合物 - Google Patents

实体瘤治疗用医药组合物 Download PDF

Info

Publication number
CN117794544A
CN117794544A CN202280052902.2A CN202280052902A CN117794544A CN 117794544 A CN117794544 A CN 117794544A CN 202280052902 A CN202280052902 A CN 202280052902A CN 117794544 A CN117794544 A CN 117794544A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052902.2A
Other languages
English (en)
Chinese (zh)
Inventor
玉井俊行
永尾聪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN117794544A publication Critical patent/CN117794544A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280052902.2A 2021-09-08 2022-09-06 实体瘤治疗用医药组合物 Pending CN117794544A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-146389 2021-09-08
JP2021146389 2021-09-08
PCT/JP2022/033458 WO2023038030A1 (ja) 2021-09-08 2022-09-06 固形腫瘍治療用医薬組成物

Publications (1)

Publication Number Publication Date
CN117794544A true CN117794544A (zh) 2024-03-29

Family

ID=85507597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052902.2A Pending CN117794544A (zh) 2021-09-08 2022-09-06 实体瘤治疗用医药组合物

Country Status (9)

Country Link
US (1) US20250222003A1 (https=)
EP (1) EP4364742A4 (https=)
JP (1) JP7445826B2 (https=)
KR (1) KR20240056487A (https=)
CN (1) CN117794544A (https=)
AU (1) AU2022342537A1 (https=)
CA (1) CA3227813A1 (https=)
MX (1) MX2024002060A (https=)
WO (1) WO2023038030A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) * 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
CA2986999C (en) 2015-06-23 2023-08-08 Eisai R&D Management Co., Ltd. Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide
US12303505B2 (en) * 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
EP4051278B1 (en) * 2019-10-29 2025-12-17 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer

Also Published As

Publication number Publication date
MX2024002060A (es) 2024-03-01
KR20240056487A (ko) 2024-04-30
JP7445826B2 (ja) 2024-03-07
WO2023038030A1 (ja) 2023-03-16
EP4364742A4 (en) 2025-07-02
JPWO2023038030A1 (https=) 2023-03-16
EP4364742A1 (en) 2024-05-08
TW202327613A (zh) 2023-07-16
AU2022342537A1 (en) 2024-02-15
CA3227813A1 (en) 2023-03-16
US20250222003A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
CN103945849B (zh) 癌症的联合治疗
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
US9700565B2 (en) Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
TW202227088A (zh) 組合療法
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
CN117794544A (zh) 实体瘤治疗用医药组合物
US20250213556A1 (en) Combination therapy for treating cancer
TWI908143B (zh) 瑞博西尼藥物組成物用於治療癌症之用途
CN121443295A (zh) 治疗前列腺癌的方法
US20250235448A1 (en) Combination therapy for treating cancer
CN118678960A (zh) 用于治疗癌症的方法和组合物
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
US20190160054A1 (en) Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
TW202404592A (zh) 用於治療癌症之組合療法
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
TW202525278A (zh) 治療慢性腎病及高血壓之方法
CN115666565A (zh) 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
NZ790981A (en) Methods of treating eosinophilic esophagitis
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
HK1185808A1 (zh) 用於治疗癌症的包含威罗菲尼和干扰素的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination